2000 Fiscal Year Final Research Report Summary
Study on growth suppression and chemoprevention of lung cancer by cyclooxygenase 2 inhibitor
| Project/Area Number |
11670604
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Aichi Cancer Center Research Institute |
|---|
Principal Investigator |
HIDA Toyoaki Research Institute, Aichi Cancer Center Research Institute, Researcher, 研究所, 研究員 (80250249)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TAKAHASHI Takashi Molecular Oncology, Aichi Cancer Center Research Institute, Chief, 分子腫瘍学部, 部長 (50231395)
SUGIURA Takahiko Research Institute, Aichi Cancer Center Research Institute, Researcher, 研究所, 研究員 (50117826)
|
|---|
| Project Period (FY) |
1999 – 2000
|
| Keywords | Lung cancer / prognosis / cyclooxygenase 2 / chemotherapy / radiation / COX-2 inhibitor / apoptosis / combination therapy |
|---|
| Research Abstract |
We recently reported that an increased expression of COX-2 was frequently seen in a specific type of lung cancer, i.e., adenocarcinoma, and was possibly associated with its invasion and metastases. We have also shown the presence of a significant relationship between elevated COX-2 expression and shortened patient survival in a cohort of patients with stage I disease.
We report here that COX-2 inhibitor could inhibit proliferation of non-small cell lung cancer (NSCLC) cell lines in vitro in a dose-dependent manner, in part by inducing apoptosis even at clinically achievable low concentrations. Our observations also suggested that the state of COX-2 expression in NSCLC cells might influence their responsiveness to COX-2 inhibitors. Moreover, we found that COX-2 inhibitor, when used in combination at clinically achievable concentrations, reduced the IC_<50> values of various anticancer agents by up to 77%, although the levels of reduction varied considerably. In radiation sensitivity, COX-2 inhibitor was shown to have an additive effect on the efficacy of irradiation. Since our previous studies have indicated that significantly increased COX-2 expression is present in up to 70% of adenocarcinoma cases, the present findings are of great clinical interest and the recent development of next generation, highly selective COX-2 inhibitors should lead to even greater efficacy for the adjunct use with various anticancer agents in the treatment of high risk patients without compromising their quality of life.
|
